Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      AZD9291, a mutant‐selective EGFR inhibitor, as first‐line treatment for EGFR mutation‐positive advanced non‐small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort

      J Clin Oncol

      Read this article at

      ScienceOpen
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Oncology & Radiotherapy, Medicine

          Comments

          Comment on this article